background
sinc
earli
decemb
novel
coronaviru
diseas
caus
pneumonia
epidem
wuhan
hubei
provinc
china
studi
aim
investig
factor
affect
progress
pneumonia
patient
associ
result
use
evalu
prognosi
find
optim
treatment
regimen
pneumonia
method
patient
test
posit
base
nucleic
acid
detect
includ
studi
patient
admit
three
tertiari
hospit
wuhan
decemb
januari
individu
data
laboratori
indic
imag
characterist
clinic
data
collect
statist
analysi
perform
base
clinic
type
result
patient
divid
progress
group
improvementstabil
group
continu
variabl
analyz
use
independ
sampl
ttest
mannwhitney
u
test
categor
variabl
analyz
use
chisquar
test
fisher
exact
test
logist
regress
analysi
perform
explor
risk
factor
diseas
progress
seventyeight
patient
pneumonia
met
inclus
criteria
includ
studi
efficaci
evalu
week
hospit
indic
patient
deterior
patient
improvedstabil
patient
progress
group
significantli
older
diseas
improvementstabil
group
year
vs
year
u
p
progress
group
significantli
higher
proport
patient
histori
smoke
improvementstabil
group
vs
p
patient
fever
common
initi
symptom
maximum
bodi
temperatur
admiss
significantli
higher
progress
group
improvementstabil
group
vs
p
moreov
proport
patient
respiratori
failur
vs
respiratori
rate
breathsmin
vs
breathsmin
significantli
higher
progress
group
improvementstabil
group
creactiv
protein
significantli
elev
progress
group
compar
improvementstabil
group
mgl
vs
mgl
albumin
significantli
lower
progress
group
improvementstabil
group
gl
vs
gl
u
p
patient
progress
group
like
receiv
highlevel
respiratori
support
improvementstabil
group
multivari
logist
analysi
indic
age
ci
p
histori
smoke
ci
p
maximum
bodi
temperatur
admiss
ci
p
respiratori
failur
ci
p
albumin
ci
p
creactiv
protein
ci
p
risk
factor
diseas
progress
conclus
sever
factor
led
progress
pneumonia
identifi
includ
age
histori
smoke
maximum
bodi
temperatur
admiss
respiratori
failur
albumin
creactiv
protein
result
use
enhanc
abil
manag
pneumonia
sinc
decemb
unexplain
pneumonia
success
identifi
sever
patient
histori
exposur
huanan
seafood
market
multipl
hospit
citi
wuhan
hubei
provinc
china
patient
confirm
acut
respiratori
infect
ie
pneumonia
caus
novel
coronaviru
clinic
investig
confirm
case
case
observ
shown
number
patient
histori
exposur
huanan
seafood
market
rapidli
increas
februari
confirm
case
novel
coronaviru
diseas
china
previou
studi
found
highest
temperatur
dyspnea
respiratori
rate
white
blood
cell
count
neutrophil
count
lymphocyt
count
ddimer
albumin
procalcitonin
risk
factor
icu
care
patient
therefor
absolut
necessari
evalu
possibl
factor
affect
progress
diseas
patient
investig
factor
affect
outcom
patient
evalu
prognosi
improv
treatment
patient
associ
pneumonia
hope
reduc
mortal
studi
conduct
accord
declar
helsinki
requir
written
inform
consent
waiv
given
context
emerg
infecti
diseas
patient
includ
studi
diagnos
associ
pneumonia
decemb
januari
hospit
one
three
tertiari
hospit
wuhan
two
week
specif
inclus
criteria
patient
confirm
diagnosi
posit
test
result
nucleic
acid
realtim
fluoresc
revers
transcriptionpolymeras
chain
reaction
rtpcr
accord
diagnosi
treatment
protocol
novel
coronaviru
infectioninduc
pneumonia
version
trial
patient
hospit
two
week
prepar
manuscript
die
hospit
recov
discharg
patient
evalu
clinic
type
upon
admiss
accord
diagnosi
treatment
protocol
novel
coronaviru
infectioninduc
pneumonia
version
trial
specif
clinic
type
includ
common
fever
respiratori
tract
infect
symptom
imag
indic
pneumonia
sever
follow
condit
respiratori
distress
respiratori
rate
rr
breathsmin
ii
oxygen
satur
rest
iii
partial
pressur
oxygen
pao
fraction
inspir
oxygen
fio
mmhg
mmhg
kpa
critic
follow
condit
respiratori
failur
requir
mechan
ventil
ii
shock
iii
concomit
failur
organ
requir
intens
care
unit
icu
monitor
treatment
addit
clinic
type
laboratori
indic
patient
measur
detail
list
biochem
test
section
two
week
hospit
diseas
evalu
clinic
type
perform
patient
accord
diagnosi
treatment
protocol
novel
coronaviru
infectioninduc
pneumonia
version
trial
patient
divid
progress
group
improvementstabil
group
base
clinic
type
result
specif
criteria
follow
progress
group
commontyp
chang
severeor
criticaltyp
death
severetyp
chang
criticaltyp
death
criticaltyp
progress
death
improvementstabil
group
common
sever
criticaltyp
remain
unchang
severetyp
chang
commontyp
criticaltyp
chang
severeor
commontyp
creatinin
albumin
infect
indic
procalcitonin
creactiv
protein
ddimer
partial
pressur
oxygen
person
data
clinic
data
patient
includ
studi
collect
person
data
includ
sex
age
epidemiolog
histori
histori
smoke
comorbid
eg
chronic
obstruct
pulmonari
diseas
copd
cancer
hypertens
andor
diabet
clinic
data
includ
initi
symptom
clinic
present
vital
sign
therapeut
drugus
respiratori
support
diseas
outcom
categor
variabl
present
number
percentag
analyz
use
chisquar
test
fisher
exact
test
continu
variabl
normal
distribut
express
deviat
analyz
use
independ
sampl
ttest
skew
distribut
shown
median
q
q
analyz
use
mannwhitney
u
test
univari
multivari
logist
regress
analysi
adopt
identifi
risk
factor
diseas
progress
variabl
univari
analysi
p
valu
enter
forwardstepwis
multivari
logist
regress
analysi
spss
softwar
version
spss
inc
chicago
illinoi
usa
use
statist
analysi
twosid
p
consid
statist
signific
present
studi
patient
associ
pneumonia
includ
male
femal
patient
histori
exposur
huanan
seafood
market
median
age
q
q
year
patient
age
year
patient
progress
group
significantli
older
improvementstabil
group
vs
u
p
studi
suggest
progress
group
significantli
higher
proport
patient
histori
smoke
improvementstabil
group
vs
p
twenti
patient
comorbid
hypertens
common
signific
differ
sex
two
group
p
signific
differ
comorbid
includ
hypertens
diabet
chronic
obstruct
pulmonari
diseas
copd
cancer
other
two
group
p
fever
primari
initi
symptom
fiftyseven
patient
sought
treatment
fever
commonli
observ
maximum
bodi
temperatur
patient
maximum
bodi
temperatur
admiss
significantli
higher
progress
group
improvementstabil
group
breathsmin
signific
differ
blood
oxygen
satur
heart
rate
two
group
p
eight
patient
sever
ill
proport
sever
ill
patient
significantli
differ
two
group
vs
p
tabl
studi
relev
laboratori
indic
patient
among
hospit
patient
common
treatment
combin
antiviralsantibacteri
glucocorticoid
commonli
use
antivir
drug
ribavirin
commonli
use
antibacteri
drug
cephalosporin
quinolon
antibiot
median
glucocorticoid
dose
mg
intraven
iv
everi
day
qd
signific
differ
two
group
mg
qd
iv
vs
mg
qd
iv
proport
patient
use
differ
drug
protocol
includ
antiviralsantibacteri
antiviralsantibacteri
glucocorticoid
antiviralsantibacteri
gamma
globulin
antiviralsantibacteri
thymosin
antiviralsantibacteri
lopinavir
improvementstabil
group
progress
group
significantli
differ
p
hospit
patient
degre
hypoxia
nasal
cannula
common
form
respiratori
support
follow
continu
noninvas
posit
pressur
ventil
progress
group
typic
sever
hypoxia
significantli
like
receiv
higher
level
respiratori
support
compar
improvementstabil
group
p
tabl
result
univari
logist
analysi
found
age
odd
ratio
p
risk
factor
diseas
progress
tabl
coronaviru
highli
contagi
pathogen
found
sever
domest
anim
pet
human
caus
varieti
acut
chronic
diseas
current
six
coronavirus
known
infect
human
includ
compris
middl
east
respiratori
syndromerel
coronaviru
mersrcov
sever
acut
respiratori
syndromerel
coronaviru
sarsrcov
coronaviru
gradual
becom
popular
topic
research
field
virolog
outbreak
sarsrcov
mersrcov
current
outbreak
due
novel
coronaviru
isol
lower
respiratori
tract
patient
unexplain
pneumonia
wuhan
china
current
sourc
pathogenesi
remain
unclear
uniform
diagnost
treatment
standard
unfortun
certain
patient
diseas
progress
rapidli
respiratori
failur
occur
within
short
time
even
lead
death
therefor
investig
diseas
outcom
factor
affect
outcom
patient
pneumonia
three
tertiari
hospit
wuhan
provid
theoret
basi
improv
hospit
effort
effect
treat
patient
pneumonia
present
studi
includ
patient
diagnos
patient
evalu
therapeut
efficaci
least
two
week
hospit
result
indic
progress
patient
improvementstabil
patient
patient
younger
year
median
age
patient
year
suggest
middleag
peopl
suscept
also
age
patient
progress
group
significantli
higher
improvementstabil
group
multivari
logist
analysi
indic
higher
age
risk
factor
diseas
progress
elderli
individu
physic
frail
like
sever
comorbid
increas
risk
pneumonia
also
affect
prognosi
assess
comorbid
essenti
compon
determin
prognosi
sever
diseas
especi
pneumonia
probabl
small
sampl
size
signific
differ
comorbid
includ
hypertens
diabet
copd
cancer
other
two
group
potenti
impact
comorbid
diseas
outcom
patient
pneumonia
requir
observ
research
proport
patient
histori
smoke
significantli
higher
progress
group
compar
improvementstabil
group
suggest
smoke
associ
diseas
progress
signific
symptom
sar
bodi
temperatur
two
week
addit
patient
diagnos
mer
present
fever
present
studi
patient
sought
treatment
fever
result
show
maximum
bodi
temperatur
admiss
progress
group
significantli
higher
improvementstabil
group
multivari
logist
model
indic
higher
temperatur
risk
factor
diseas
progress
therefor
patient
present
high
fever
long
fever
durat
rapid
fever
progress
monitor
close
clinic
diagnosi
treatment
order
avoid
complic
associ
high
fever
lead
poor
prognosi
vital
sign
essenti
indic
assess
current
symptom
patient
respiratori
system
indic
respiratori
rate
whether
respiratori
failur
occur
particularli
crucial
assess
condit
sever
patient
present
studi
found
median
respiratori
rate
patient
pneumonia
breathsmin
higher
normal
respiratori
rate
breathsmin
respiratori
rate
proport
patient
respiratori
failur
progress
group
significantli
higher
improvementstabil
group
abnorm
respiratori
indic
directli
reflect
extent
lung
invas
multivari
logist
model
reveal
respiratori
failur
risk
factor
diseas
progress
therefor
respiratori
indic
one
top
prioriti
efficaci
evalu
present
studi
suggest
elev
creactiv
protein
decreas
albumin
factor
associ
poor
prognosi
infect
albumin
intuit
index
nutrit
statu
bodi
albumin
decreas
bodi
lose
resist
viru
lead
diseas
progress
elev
creactiv
protein
import
inflammatori
index
addit
abnorm
blood
coagul
function
close
monitor
dynam
chang
indic
signific
proactiv
effect
understand
chang
patient
condit
addit
studi
shown
lymphocyt
main
target
cell
viral
infect
viral
infect
human
bodi
primarili
involv
damag
immun
system
present
decreas
absolut
number
lymphocyt
present
studi
find
indic
signific
assess
outcom
patient
correl
requir
investig
studi
includ
ct
scan
characterist
patient
pneumonia
analysi
suggest
extent
characterist
lesion
statist
signific
diseas
outcom
howev
use
ct
scan
earlier
stage
diseas
assess
still
great
signific
earli
detect
earli
diagnosi
improv
prognosi
appropri
antibiot
treatment
administ
prevent
secondari
infect
critic
type
viral
pneumonia
analyz
diagnosi
treatment
protocol
patient
pneumonia
result
suggest
patient
undergo
antivir
treatment
also
proactiv
undergo
antibacteri
treatment
whether
viral
pneumonia
treat
glucocorticoid
controversi
research
believ
use
glucocorticoid
viral
pneumonia
easili
aggrav
diseas
increas
risk
secondari
infect
lead
increas
mortal
thu
advoc
use
glucocorticoid
studi
suggest
use
appropri
dose
glucocorticoid
earli
stage
could
inhibit
elev
secret
inflammatori
cytokin
due
excess
activ
immun
cell
viral
infect
therebi
prevent
continu
exacerb
lung
injuri
found
combin
antivir
antibacteri
glucocorticoid
highest
use
rate
treatment
pneumonia
moreov
research
suggest
use
thymosin
gamma
globulin
earli
stage
infect
improv
patient
immun
addit
current
ongo
relat
studi
suggest
hiv
structur
similar
thu
certain
research
propos
antihiv
drug
lopinavir
may
play
role
inhibit
studi
comparison
efficaci
antiviralsantibacteri
antiviralsantibacteri
glucocorticoid
antiviralsantibacteri
gamma
globulin
antiviralsantibacteri
thymosin
antiviralsantibacteri
lopinavir
perform
result
suggest
drug
protocol
affect
diseas
outcom
therefor
studi
includ
drug
treatment
pneumonia
character
acut
onset
rapid
progress
therefor
earli
use
glucocorticoid
proactiv
antivir
antibacteri
treatment
comprehens
evalu
may
block
inflammatori
cascad
caus
sever
viral
infect
prevent
acut
inflamm
lung
damag
caus
infect
progress
acut
respiratori
distress
syndrom
respiratori
support
essenti
treatment
patient
sever
viral
infect
present
studi
reveal
patient
treat
respiratori
support
major
patient
administ
nasal
cannula
oxygen
continu
posit
air
pressur
progress
group
significantli
like
receiv
higher
level
respiratori
support
patient
studi
treat
invas
ventil
ecmo
due
refus
patient
famili
treat
patient
sever
viral
pneumonia
time
applic
glucocorticoid
respiratori
support
therapi
essenti
combin
person
treatment
specif
patient
limit
observ
studi
ct
scan
imag
delay
scan
time
may
introduc
bia
result
addit
rel
small
sampl
size
includ
studi
may
lead
bias
result
thu
multicent
largescal
studi
addit
research
requir
current
best
diagnost
treatment
protocol
still
investig
earli
diagnosi
dynam
monitor
prognost
factor
essenti
improv
abil
treat
covid
none
extracorpor
membran
oxygen
qd
everi
day
iv
intraven
